08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

Intercytex Group plc, Pfizer deal

Pfizer acquired undisclosed stem cell therapy assets from Intercytex's Axordia Ltd. subsidiary for $750,000. Intercytex will use the funds to support ongoing costs. In July, the biotech reduced headcount and said it had received offers...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

Axordia, Intercytex Group plc deal

Intercytex acquired Axordia for 7 million shares, valuing the stem cell company at £1.7 million ($2.5 million) based on Intercytex's close of 24p on Dec. 19, the last trading day before the deal was announced....
07:00 , Aug 14, 2006 |  BC Week In Review  |  Company News

Axordia, Lombard Medical Technologies plc deal

Axordia will use its stem cell-derived cells with LMT's PEP polymer coating technology to develop a regenerative stent that promotes local vascular repair. The duration of the deal is two and a half years. Axordia...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Axordia, Serologicals deal

Axordia and SERO's Chemicon International Inc. subsidiary (Temecula, Calif.) partnered to exclusively co-develop antibody markers from Axordia's human embryonic stem (hES) cell lines. Axordia will contribute materials for antibody generation and antibody characterization and Chemicon...